Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 21, 2008, Pages 5738-5740

  Hubbard, Robert D ^a   Dickerson, Scott H ^a   Emerson, Holly K ^a   Griffin, Robert J ^a   Reno, Michael J ^a   Hornberger, Keith R ^a   Rusnak, David W ^a   Wood, Edgar R ^a   Uehling, David E ^a   Waterson, Alex G ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

EGFR; Epidermal growth factor receptor; ErbB 2; Inhibitor; Thieno 3,2 d pyrimidines

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PYRROLIDINYLACETYLENIC THIENO[3,2 D]PYRIMIDINE DERIVATIVE; THIENO[3,2 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; COVALENT BOND; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; MOUSE; NONHUMAN; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANIMALS; CELL LINE; MICE; PROTEIN BINDING; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 53949105451     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.09.090     Document Type: Article

References (20)

1. Seymour L.K. Curr. Drug Targets 2 (2001) 117
2. Yarden Y. Eur. J. Cancer 37 (2001) S3
3. Rowinsky E.K. Annu. Rev. Med. 55 (2004) 433
4. Dumas J. Curr. Opin. Drug Discov. Devel. 4 (2001) 378
5. Baker A.J., Gibson K.H., Grudy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., Henthorn L., and Richards L. Bioorg. Med. Chem. Lett. 11 (2001) 1191
6. Bonomi P. Expert Rev. Anticancer Ther. 3 (2003) 367
7. Rusnak D.W., Lackey K.E., Wood E.R., Alligood K.J., Rhodes N., Knight W.B., and Gilmer T.M. Mol. Cancer Ther. 1 (2001) 85-94
8. Wood E.R., Trusdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., Alligood K.J., Rusnak D.W., Gilmer T.M., and Shewchuk L. Cancer Res. 64 (2004) 6652
9. Allen L.F., Eiseman I.A., Fry D.W., and Lenehan P.F. Semin. Oncol. 30 (2003) 65
10. In addition to canertinib, related irreversible agents, have also been disclosed; see. Rabindran S.K., Discafani C.M., Rosfjord E.C., Baxter M., Floyd M.B., Golas J., Hallett W.A., Johnson B.D., Nilakantan R., Overbeek E., Reich M.F., Shen R., Shi X., Tsou H.-R., Wang Y.-F., and Wissner A. Cancer Res. 64 (2004) 3958
11. Erlichman C., Hidalgo M., Boni J.P., Martins P., Quinn S.E., Zacharchuk C., Amorusi P., Adjei A.A., and Rowinsky E.K. J. Clin. Oncol. 24 (2006) 2252
12. Fry D.W. Anticancer Drug Des. 15 (2000) 3
13. Wood E.R., Shewchuk L.M., Ellis B., Brignola P., Brashear R.L., Caferro T.R., Dickerson S.D., Dickson H.D., Donaldson K.H., Gaul M., Griffin R.J., Hassell A.M., Keith B., Mullin R., Petrov K.G., Reno M.J., Rusnak D.W., Tadepalli S.M., Ulrich J.C., Wagner C.D., Vanderwall D.E., Waterson A.G., Williams J.D., White W.L., and Uehling D.E. Proc. Nat. Acad. Sci. U.S.A. 105 (2008) 2773
14. Trybulski E.J., Kramss R.H., Mangano R.M., and Rusinko A. J. Med. Chem. 33 (1990) 3190
15. Caferro, T.R.; Chamberlain, S.D.; Donaldson, K.H.; Harris, P.A.; Gaul, M.D.; Uehling, D.E.; Vanderwall, D.E. PCT Int. Appl. WO 2003053446 A1; 2003.
16. The modification data was acquired using EGFR only using methods described in Ref. 12. These analogs have not been assayed versus ErbB-2 for potential reactivity.
17. 50). Methods of testing are described in Ref. 7.
18. Ohira S. Synth. Commun. 19 (1989) 561
19. Dickson H.D., Smith S.C., and Hinkle K.W. Tetrahedron Lett. 45 (2004) 5597
20. Hydroxyl pyrrolidine 16 was constructed using similar methods used for the conversion of 13-14a, simply starting with the commercially available N-BOC-trans-4-hydroxy-d-proline methyl ester. A full examination of the possible diastereomers and the associated synthetic details will be disclosed in a future communication.